Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 11153901

Liquid ventilation.

J S Greenspan·M R Wolfson·T H Shaffer
View original source ↗Export metadata ↓

Abstract

Liquid breathing has been proposed as a means of improving gas exchange in infants with acute respiratory failure since the 1970s. In addition, there are potential clinical applications of perfluorochemical (PFC) liquids that span many specialties in medicine. The ability to lower surface tension directed the initial clinical focus on neonatal therapy in the treatment of premature lung disease. The first clinical trial of PFC ventilation was performed in neonates in 1989. Additional trials using LiquiVent (Alliance Pharmaceutical San Diego, CA), a medical grade PFC liquid, were initiated in 1993 in infants, children, and adults. These studies have concluded that liquid ventilation appeared to be safe, improve lung function, and recruit lung volume in patients from these populations. The results of such trials are encouraging, but randomized trials have yet to be completed. We await these pivotal trials, which will probably be completed in adult patients first, before this promising technique can be clinically available.

Explore related subjects

Clinical Trials as TopicFluorocarbonsHumansInfant, NewbornInfant, PrematureLiquid VentilationLung DiseasesRespiratory Distress Syndrome, NewbornComparative StudyJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J S Greenspan, M R Wolfson, T H Shaffer. 2000. Liquid ventilation.. https://doi.org/10.1053/sper.2000.20092

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2001

Use of overlapping peptide mixtures as antigens for cytokine flow cytometry.

Intracellular cytokine staining and flow cytometry can be used to measure T-cell responses to defined antigens. Although CD8+ T-cell responses to soluble proteins are inefficiently detected by this approach, peptides can be used as antigens. Using overlapping peptides spanning an entire protein sequence, CD8+ T-cell responses can be detected to multiple epitopes, regardless of HLA type. In this study, overlapping peptide mixes of various lengths were compared and 15 amino acid peptides with 11 amino acid overlaps were found to stimulate both CD4+ and CD8+ T-cell responses. Such peptide mixes stimulated CD4+ T-cell responses equivalent to those observed with whole recombinant protein, while simultaneously stimulating CD8+ T-cell responses much higher than those observed with whole protein. Although 8-12 amino acid peptides produced the highest level of CD8+ T-cell responses, 15 amino acid peptides were still very effective. Peptides that were 20 amino acids in length, however, did not stimulate strong CD8+ T-cell responses at the same peptide dose. The cytokine responses to individual epitopes added up approximately to the response to the entire mix, demonstrating that large mixes can detect responses in a quantitative fashion. Unlike whole protein antigens, peptide mixes were effective at stimulating responses in both cryopreserved PBMC and blood stored for 24 h at room temperature. Thus, overlapping 15 amino acid peptide mixes may facilitate the analysis of antigen-specific CD4+ and CD8+ T-cell responses by cytokine flow cytometry, using clinical specimens that include shipped blood or cryopreserved PBMC.

Clinical Trials as Topic↗
PubMed2001

Preventing severe mental illnesses--new prospects and ethical challenges.

We review some exciting recent developments in studies of psychoses in general and schizophrenia in particular that offer hope such illnesses can be identified and treated early. Early treatment promises better outcomes for both the affected individuals and their families, and perhaps even the prospect of true prevention. But testing such interventions in vulnerable patients can raise ethical difficulties that if not adequately addressed may harm patients and hamper the development of these interventions. We believe there are appropriate ways of dealing with the ethical problems in the early intervention field, though we also suggest that additional work on both scientific and ethical fronts will need to be done to make these ways real. As a start toward that end, we have summarized a number of the debates in the field and from the following articles, and have distilled five 'points to consider' that interested parties will need to take into account.

Clinical Trials as Topic↗
PubMed2001

Ethics and early intervention in psychosis: keeping up the pace and staying in step.

The intense clinical and research interest in early psychosis in recent years has highlighted a range of ethical issues which need to be considered carefully. Our perspective is based on 16 years of clinical and research experience with young people at this phase of illness as well as the research contributions of many others. We discuss the ethical dilemmas in relation to the three key foci, which make up the early psychosis paradigm. These are the pre-psychotic or prodromal phase, the period of untreated psychosis and the first psychotic episode and the critical period of recovery, which follows this. Most attention is devoted to the pre-psychotic period, however ethical considerations related to research in the other two clinical foci are briefly covered as well. Our contention is that the ethical issues are essentially identical to those arising in early intervention research in mainstream medicine. This has been concealed by inconsistency and emotion, which has great potential to confuse, politicize and derail rational debate. The legacy of the isolation of psychiatry from medicine and consequent prejudice and stigma in the professional as well as the public mind seems to be fueling a tendency in some societies to view psychiatric research as qualitatively different from other medical research. Sound clinical research data should be allowed to illuminate the options for potential consumers across all phases of illness. The alternative is research paralysis, which would force clinical practice to expand blindly without an evidence base.

Clinical Trials as Topic↗